Scheler, Max
Lehrnbecher, Thomas
Groll, Andreas H.
Volland, Ruth
Laws, Hans-Jürgen
Ammann, Roland A.
Agyeman, Philipp
Attarbaschi, Andishe
Lux, Margaux
Simon, Arne http://orcid.org/0000-0001-9558-3330
Funding for this research was provided by:
Deutsche Gesellschaft für Pädiatrische Infektiologie
Article History
Received: 1 May 2020
Accepted: 2 June 2020
First Online: 10 June 2020
Compliance with ethical standards
:
: AS is the second chairman of the DGPI and the coordinator of the German AWMF FN Guideline (Reg. No 048/14). TL is the Chairman of the Working Group on Infectious complications in children with cancer of the GPOH and the working group Febrile Neutropenia of the DGPI. TL has received research grants from Gilead Sciences, is a consultant to Astellas, Basilea, Gilead Sciences, and Merck/MSD, and served at the speaker´s bureau of Astellas, Gilead Sciences, Merck/MSD, and Sanofi Pasteur. AHG has received research grants from Gilead, Merck, Sharp & Dohme, Pfizer; is/has been a consultant to Amplyx, Astellas, Basilea, F2G, Gilead, Merck, Sharp & Dohme, Pfizer, Schering-Plough, Scynexis; and is/has been on the speaker’s bureau of Astellas, Basilea, F2G, Gilead, Merck, Sharp & Dohme, Pfizer, Schering-Plough and Zeneus/Cephalon.